Processa Pharmaceuticals, Inc. (PCSA) News
Filter PCSA News Items
PCSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PCSA News Highlights
- PCSA's 30 day story count now stands at 3.
- Over the past 7 days, the trend for PCSA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, MD and DRUG are the most mentioned tickers in articles about PCSA.
Latest PCSA News From Around the Web
Below are the latest news stories about PROCESSA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PCSA as an investment opportunity.
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineFDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU exposure much greater than that from capecitabine Company to conduct Fireside Chat at 4:30PM ET on December 20, 2023 HANOVER, MD, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company fo |
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation CapecitabineFDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial HANOVER, MD, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the outcomes from a successful meeting with the U.S. Food and Drug Admini |
Is Processa Pharmaceuticals (NASDAQ:PCSA) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceHANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present virtually at the MedInvest Oncology Investor Conference. The conference is being held on December 5 – 6, 2023 in |
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookHANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO George Ng has issued a letter to shareholders. Dear Processa Pharmaceuticals Shareholders: Following Processa’s business pivot to focus on oncology drug product development, |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! |
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonHanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Board of Directors since we were formed in 2017 and was previously on the Board of Directors of Promet Therapeutics, LLC, our predecessor. He was 83 years old. “We are all saddened by the sudden passing of our friend and one of our founding board members, Virgil Tho |
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasHANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas. The conference is being held on Novembe |
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion LeadersCompany To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces the formation of its Oncology Adviso |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the workweek with a detailed breakdown of the biggest pre-market stock movers for Monday morning! |